Marchetti T, Cohen M, de Moerloose P
Laboratory of Hormonology, Maternity, Geneva University Hospitals, 1211 Geneva 14, Switzerland.
Clin Dev Immunol. 2013;2013:159124. doi: 10.1155/2013/159124. Epub 2013 Jul 30.
Antiphospholipid syndrome (APS) is an acquired thrombophilia with clinical manifestations associated with the presence of antiphospholipid antibodies (aPL) in patient plasma. Obstetrical APS is a complex entity that may affect both mother and fetus throughout the entire pregnancy with high morbidity. Clinical complications are as various as recurrent fetal losses, stillbirth, intrauterine growth restriction (IUGR), and preeclampsia. Pathogenesis of aPL targets trophoblastic cells directly, mainly via proapoptotic, proinflammatory mechanisms, and uncontrolled immunomodulatory responses. Actual first-line treatment is limited to low-dose aspirin (LDA) and low-molecular weight heparin (LMWH) and still failed in 30% of the cases. APS pregnancies should be a major field in obstetrical research, and new therapeutics are still in progress.
抗磷脂综合征（APS）是一种获得性易栓症，其临床表现与患者血浆中抗磷脂抗体（aPL）的存在有关。产科抗磷脂综合征是一个复杂的病症，在整个孕期可能会影响母亲和胎儿，发病率很高。临床并发症多种多样，包括反复流产、死产、胎儿生长受限（IUGR）和先兆子痫。抗磷脂抗体的发病机制主要通过促凋亡、促炎机制以及不受控制的免疫调节反应直接靶向滋养层细胞。目前的一线治疗仅限于低剂量阿司匹林（LDA）和低分子量肝素（LMWH），但仍有30%的病例治疗失败。抗磷脂综合征妊娠应是产科研究的一个主要领域，新的治疗方法仍在研发中。
